Merck & Co And Galapagos sign obesity and diabetes deal
This article was originally published in Scrip
Merck & Cois to pay Galapagos€1.5 million up-front and up to €170 million in development and regulatory milestones for the rights to license obesity and diabetes drug candidates developed by the Belgian drug discovery company. Merck will have the exclusive option to develop in clinical trials and commercialise candidates discovered in Galapagos's SilenceSelect target discovery platform for identifying novel targets in obesity and diabetes. Galapagos will be responsible for the discovery and pre-clinical development of such treatments and may begin Phase I clinical studies. The company develop and commercialise any compounds for which Merck does not exercise its exclusive option. Merck may also pay sales milestones and royalties upon the commercialisation of any products developed in the agreement.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.